The Adipose Paradox: Impaired Assembly, Enhanced Output

There’s a strange contradiction in the current data: aged adipose tissue (AT) macrophages show significantly reduced intracellular ASC speck formation and slower caspase-1 kinetics compared to younger cells (AJP Lung), yet they’re clearly the primary source of systemic IL-1β and IL-18 (Academic OUP). It seems the inflammatory process in visceral fat isn't a failed local defense, but a specialized export operation.

The Hypothesis: ESCRT-III Co-option for "Cloaked" Propagation

I suspect the aging adipose macrophage doesn’t actually have defective inflammasome machinery. Instead, it’s likely shifted from a pyroptotic (cell-death) program to a secretory one. In this model, the ESCRT-III complex—which usually repairs GSDMD-induced membrane pores to prevent cell death (Frontiers)—becomes hyper-activated in the aged AT environment.

Rather than just sealing the pores, the ESCRT machinery facilitates the vesicular shedding of GSDMD-NT/ASC complexes. This results in the release of "enveloped" ASC specks—extracellular aggregates protected by a host-derived lipid bilayer. These stealth carriers bypass the hepatic clearance mechanisms that usually neutralize naked protein aggregates, allowing for the prion-like seeding of distal organs (PMC).

Mechanistic Reasoning

The logic rests on a few key points:

1. The Potassium Threshold Link: Chronic potassium leaks in aged cells lower the threshold for NLRP3 activation but aren't always enough to trigger the massive efflux required for full pyroptotic rupture. This sub-lethal state allows GSDMD pores to form without killing the cell (PMC).
2. ESCRT-III as the Pivot: With persistent calcium influx through these sub-lethal pores, ESCRT-III recruitment becomes constitutive. I hypothesize this triggers an abnormal budding process where oligomerized ASC specks are packaged into microvesicles alongside mature cytokines.
3. Immune Evasion: Naked ASC specks are highly pro-inflammatory and easily detected by the reticuloendothelial system. By packaging these specks into membrane-bound vesicles, the aged adipose tissue effectively disguises the inflammatory cargo. This lets it reach the vascular endothelium and the blood-brain barrier undetected until the vesicle fuses with a target cell.

Testability and Falsification

We can test this through several experiments:

• Vesicular Analysis: Isolation of plasma microvesicles from aged vs. young mice should show a significantly higher concentration of vesicle-encapsulated ASC in the older group. These should be enriched with markers of ESCRT-III (e.g., CHMP4B) and show an adipose origin (via Fabp4-cre tracing).
• Pharmacological Inhibition: If we treat aged mice with ESCRT-III or VPS4 inhibitors, we’d expect local adipose pyroptosis to increase—removing the stealth source—while systemic markers of inflammaging and distal organ damage actually decrease (PMC).
• Falsification: If extracellular ASC specks in the serum of aged subjects turn out to be mostly "naked," or if an ESCRT-III knockdown leads to an increase in systemic IL-1β, the hypothesis is wrong.

By treating the adipose "warehouse" as a factory for cloaked inflammatory seeds, we stop viewing obesity as a mere storage failure and see it instead as an active, vesicular-mediated immune offensive against the rest of the organism.